Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 2:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 27 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oropharyngeal Mucositis Clear all
Terminated Phase 3 Interventional

S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients With Newly Diagnosed Cancer of the Mouth or Throat

NCT00006994
View directory record Official record
Conditions
Cancer-related Problem/Condition, Head and Neck Cancer, Pain
Interventions
glutamine, radiation therapy, l-glutamine placebo
Dietary Supplement · Radiation · Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 90 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
106
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2015 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional Results available

A Pilot Study at a Single-Institution of Pregabalin in the Management of Mucositis Pain in Patients Undergoing Chemoradiation Therapy to the Head and Neck.

NCT02277548
View directory record Official record
Conditions
Oropharyngeal Cancer, Squamous Cell Carcinoma to the Head and Neck
Interventions
Lyrica 300 mg, Placebo
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis

NCT05369234
View directory record Official record
Conditions
Oral Cavity Cancer, Head and Neck Cancers - Tonsils, Esophageal Cancer, Laryngeal Cancer, Oropharynx Cancer, Mediastinal Cancer, Chest Wall Tumor, Radiation Mucositis
Interventions
100% Aloe Vera Juice, Magic Mouthwash, Salt and Baking soda rinse, Carafate
Dietary Supplement · Combination Product · Drug
Lead sponsor
Covenant Health Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Phase 2 Interventional Results available

Chemo/XRT +/- Amifostine to Assess Outcomes Related to Xerostomia, Mucositis, & Dysphagia

NCT00503776
View directory record Official record
Conditions
Dysphagia, Head and Neck Cancer, Mucositis, Xerostomia
Interventions
exercise intervention, amifostine trihydrate, therapeutic dietary intervention
Behavioral · Drug · Procedure
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
21 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 19, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2024 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Effects of GC4419 on Radiation Induced Oral Mucositis in Patients With Head/Neck Cancer

NCT02508389
View directory record Official record
Conditions
Radiation Induced Oral Mucositis
Interventions
Low Dose GC4419: 30mg/day, High Dose GC4419: 90mg/day, Placebo, Intensity-Modulated Radiation Therapy, Cisplatin
Drug · Radiation
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
60
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT01156142
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Oral Complications of Radiation Therapy, Pain
Interventions
doxepin hydrochloride, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
120
States / cities
Scottsdale, Arizona • Hartford, Connecticut • Jacksonville, Florida + 77 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2Phase 3 Interventional

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00002533
View directory record Official record
Conditions
Head and Neck Cancer, Infection, Oral Complications
Interventions
fluconazole, radiation therapy
Drug · Radiation
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2006
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

DOM-INNATE: Study of SGX942 for the Treatment of Oral Mucositis in Patients With Concomitant Chemoradiation Therapy for Head and Neck Cancer

NCT03237325
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity and Oropharynx, Oral Mucositis
Interventions
SGX942, Placebo
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
32
States / cities
Tucson, Arizona • Loma Linda, California • Pomona, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00008398
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications, Radiation Toxicity
Interventions
sargramostim, quality-of-life assessment, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
217
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 167 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2013 · Synced Jul 23, 2026, 2:07 PM EDT
Not listed Phase 3 Interventional

Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer

NCT00022373
View directory record Official record
Conditions
Head and Neck Cancer, Oral Complications of Radiation Therapy, Radiation Toxicity
Interventions
iseganan HCl oral solution, management of therapy complications
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2014 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Phase 3 Interventional Results available

Palifermin in Lessening Oral Mucositis in Patients Undergoing Radiation Therapy and Chemotherapy for Locally Advanced Head and Neck Cancer

NCT00360971
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis, Pain, Radiation Toxicity
Interventions
palifermin, cisplatin, placebo, neck dissection, radiation therapy
Biological · Drug · Other + 2 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Scottsdale, Arizona • Auburn, California • Burbank, California + 40 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 1 Interventional

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

NCT01921426
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Oropharynx
Interventions
GC4419
Drug
Lead sponsor
Galera Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
10
States / cities
Lakeland, Florida • Iowa City, Iowa • St Louis, Missouri + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2016 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Phase 2 Interventional Results available

Selenomethionine in Reducing Mucositis in Patients With Locally Advanced Head and Neck Cancer Who Are Receiving Cisplatin and Radiation Therapy

NCT01682031
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Mucositis, Radiation Toxicity, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Oropharynx, Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Xerostomia
Interventions
selenomethionine, placebo, cisplatin, radiation therapy, quality-of-life assessment
Dietary Supplement · Other · Drug + 2 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional

Feasibility Study of Low Level Light Therapy for Prevention of Oropharyngeal Mucositis in Pediatric Transplants Patients

NCT02119897
View directory record Official record
Conditions
Oropharyngeal Mucositis, Myeloablative Hematopoietic Cell Transplantation, Low Level Light Therapy
Interventions
Low Level Light Therapy
Device
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
4 Years to 25 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

Randomized Amifostine For SCCHN

NCT00095927
View directory record Official record
Conditions
Chemotherapeutic Agent Toxicity, Head and Neck Cancer, Mucositis, Radiation Toxicity, Xerostomia
Interventions
Amifostine, Carboplatin, Paclitaxel, radiation
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
9
States / cities
Sanford, Maine • Boston, Massachusetts • Concord, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional

EC-18 for Oral Mucositis in Patients With Concomitant Chemoirradiation

NCT03200340
View directory record Official record
Conditions
Stomatitis
Interventions
EC-18, Placebo
Drug
Lead sponsor
Enzychem Lifesciences Corporation
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
20
States / cities
Long Beach, California • Los Angeles, California • Miami, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Phase 2Phase 3 Interventional

Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

NCT04648020
View directory record Official record
Conditions
Chemoradiotherapy-Induced Severe Oral Mucositis
Interventions
Clonidine HCl Mucoadhesive Buccal Tablet, Placebo Mucoadhesive Buccal Tablet
Drug
Lead sponsor
Monopar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
48
States / cities
Little Rock, Arkansas • Fountain Valley, California • Long Beach, California + 42 more
Source: ClinicalTrials.gov public record
Updated May 30, 2023 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Not applicable Interventional Results available

Acupuncture in Reducing the Severity of Chemoradiation-induced Mucositis in Patients With Oropharyngeal Cancer

NCT01883908
View directory record Official record
Conditions
Mucositis, Oropharyngeal Cancer
Interventions
Acupuncture with Seirin® needles, Usual medical care
Device · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Jul 23, 2026, 2:07 PM EDT
Terminated Phase 2 Interventional Results available

Combination Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

NCT00352118
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
filgrastim, pegfilgrastim, cisplatin, docetaxel, fluorouracil, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 27, 2017 · Synced Jul 23, 2026, 2:07 PM EDT
Active, not recruiting Phase 2 Interventional

RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer

NCT05966194
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Intensity Modulated Radiation Therapy (IMRT), Cisplatin for injection 100 mg/m2
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
14
States / cities
Gilbert, Arizona • Tucson, Arizona • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Phase 2 Interventional Results available

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

NCT02123511
View directory record Official record
Conditions
Mucositis, Oral Complications, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Lymphoepithelioma of the Nasopharynx, Recurrent Lymphoepithelioma of the Oropharynx, Recurrent Mucoepidermoid Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage I Adenoid Cystic Carcinoma of the Oral Cavity, Stage I Basal Cell Carcinoma of the Lip, Stage I Lymphoepithelioma of the Nasopharynx, Stage I Lymphoepithelioma of the Oropharynx, Stage I Mucoepidermoid Carcinoma of the Oral Cavity, Stage I Salivary Gland Cancer, Stage I Squamous Cell Carcinoma of the Larynx, Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage I Squamous Cell Carcinoma of the Nasopharynx, Stage I Squamous Cell Carcinoma of the Oropharynx, Stage I Verrucous Carcinoma of the Larynx, Stage I Verrucous Carcinoma of the Oral Cavity, Stage II Adenoid Cystic Carcinoma of the Oral Cavity, Stage II Basal Cell Carcinoma of the Lip, Stage II Lymphoepithelioma of the Nasopharynx, Stage II Lymphoepithelioma of the Oropharynx, Stage II Mucoepidermoid Carcinoma of the Oral Cavity, Stage II Salivary Gland Cancer, Stage II Squamous Cell Carcinoma of the Larynx, Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Nasopharynx, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage II Verrucous Carcinoma of the Larynx, Stage II Verrucous Carcinoma of the Oral Cavity, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Basal Cell Carcinoma of the Lip, Stage III Lymphoepithelioma of the Nasopharynx, Stage III Lymphoepithelioma of the Oropharynx, Stage III Mucoepidermoid Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage III Squamous Cell Carcinoma of the Larynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage III Squamous Cell Carcinoma of the Nasopharynx, Stage III Squamous Cell Carcinoma of the Oropharynx, Stage III Verrucous Carcinoma of the Larynx, Stage III Verrucous Carcinoma of the Oral Cavity, Stage IV Lymphoepithelioma of the Nasopharynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVA Basal Cell Carcinoma of the Lip, Stage IVA Lymphoepithelioma of the Oropharynx, Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVA Salivary Gland Cancer, Stage IVA Squamous Cell Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Verrucous Carcinoma of the Larynx, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVB Basal Cell Carcinoma of the Lip, Stage IVB Lymphoepithelioma of the Oropharynx, Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVB Salivary Gland Cancer, Stage IVB Squamous Cell Carcinoma of the Larynx, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Verrucous Carcinoma of the Larynx, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity, Stage IVC Basal Cell Carcinoma of the Lip, Stage IVC Lymphoepithelioma of the Oropharynx, Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity, Stage IVC Salivary Gland Cancer, Stage IVC Squamous Cell Carcinoma of the Larynx, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Verrucous Carcinoma of the Larynx, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
Interventions
acetylcysteine, placebo, quality-of-life assessment, questionnaire administration
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
5
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Jul 23, 2026, 2:07 PM EDT
Completed Not applicable Interventional Results available

Transcutaneous Electrical Nerve Stimulation (TENS) and Head and Neck Cancer Pain (HNC) (TENS & HNC)

NCT01194466
View directory record Official record
Conditions
Head Cancer, Neck Cancer, Pain
Interventions
Transcutaneous Electrical Nerve Stimulation (TENS)
Device
Lead sponsor
Jennifer E. Lee
Other
Eligibility
18 Years to 90 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 16, 2019 · Synced Jul 23, 2026, 2:07 PM EDT